EUVIMEDEUVIMED entdecken
Crossref

Hypofractionated whole breast IMRT with HDR brachytherapy boost in early-stage breast cancer: Long-term results from a single-center

Ana Aurora Díaz-Gavela, Elia Del Cerro Peñalver, Sofía Sanchez-Garcia, Eduardo Pardo-Perez, Israel John Thuissard-Vasallo, Cristina Andreu-Vázquez, María Yolanda Molina López, Marina Pena Huertas, Luis Leonardo Guerrero-Gómez, David Sanz-Rosa, Felipe Counago Lorenzo

Brachytherapy · 2024

DOI: 10.1016/j.brachy.2024.02.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brachytherapy, 2024. Verfasst von Ana Aurora Díaz-Gavela und 10 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Therapy Department, Quironsalud Madrid University Hospital, Pozuelo de Alarcón, Madrid, Spain; Medicine Department, School of Biomedical Sc…. Hauptthemen laut MEDLINE: Breast Neoplasms, Brachytherapy, Radiation Dose Hypofractionation, Radiotherapy, Intensity-Modulated. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: European University of Madrid.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION/OBJECTIVES: The addition of a boost to the lumpectomy bed after whole-breast (WB) radiotherapy plays a key role in the treatment of patients with breast cancer (BC). The clinical benefits of a boost with high-dose-rate brachytherapy (HDR-BT) after conventional fractionation is supported by a large body of evidence. However, few studies have described its outcomes after a hypofractionated scheme. MATERIALS AND METHODS: We included all patients treated with adjuvant WB-IMRT in 15 sessions followed by a single-session HDR-BT boost with local anesthesia on an outpatient basis. RESULTS: Between 2009 and 2017, 638 patients with early-stage BC were treated according to the aforementioned protocol after breast-conserving surgery. Median follow-up was 6 years (4-11). Despite the low incidence of side effects and their slightness, we did identify an impact of breast volume on the risk of acute radiodermatitis, fibrosis, pain and edema. However, we did not identify any relationship between the volume in cubic centimeters of the BT-implant with acute or long-term side effects. 2.2% patients had an actual local relapse, 2.4% a 2nd primary in the same breast and 2.39% were diagnosed with contralateral BC. Event-free survival at 11 years was 85.5% with an overall survival of 95.7%. CONCLUSION: Adjuvant hypofractionated whole-breast IMRT followed by a single dose HDR-BT boost has a low incidence of acute and chronic toxicity and excellent oncological outcomes. However, it may be worthwhile to intensify self-care protocols and surveillance in women with large breasts who may be at increased risk of side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBrachytherapyRadiation Dose HypofractionationRadiotherapy, Intensity-ModulatedHumansFemaleMiddle AgedAgedAdultMastectomy, SegmentalAged, 80 and overNeoplasm StagingRetrospective StudiesRadiotherapy, AdjuvantTreatment OutcomeFollow-Up Studies

Stichwörter der Autor:innen

BoostBrachytherapyBreastCancerIMRTInterstitial

Autor:innen und Institutionen

  • Radiation Therapy Department, Quironsalud Madrid University Hospital, Pozuelo de Alarcón, Madrid, Spain; Medicine Department, School of Biomedical Sciences, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, S…
  • Radiation Therapy Department, Quironsalud La Luz Hospital, Madrid, Spain.
  • Radiophysics Department, Quironsalud Madrid University Hospital, Pozuelo de Alarcón, Madrid, Spain.
  • Medicine Department, School of Biomedical Sciences, Universidad Europea de Madrid, Villaviciosa de Odón, Madrid, Spain.

Förderung

  • European University of Madrid

Zitieren

APA

Díaz-Gavela, A. A., Cerro Peñalver, E. D., Sanchez-Garcia, S., Pardo-Perez, E., Thuissard-Vasallo, I. J., Andreu-Vázquez, C., Molina López, M. Y., Pena Huertas, M., Guerrero-Gómez, L. L., Sanz-Rosa, D., & Lorenzo, F. C. (2024). Hypofractionated whole breast IMRT with HDR brachytherapy boost in early-stage breast cancer: Long-term results from a single-center. Brachytherapy. https://doi.org/10.1016/j.brachy.2024.02.009

Vancouver

Díaz-Gavela AA, Cerro Peñalver ED, Sanchez-Garcia S, Pardo-Perez E, Thuissard-Vasallo IJ, Andreu-Vázquez C, et al. Hypofractionated whole breast IMRT with HDR brachytherapy boost in early-stage breast cancer: Long-term results from a single-center. Brachytherapy. 2024. doi:10.1016/j.brachy.2024.02.009

BibTeX
@article{DazGavela2024,
  author = {Díaz-Gavela, Ana Aurora and Cerro Peñalver, Elia Del and Sanchez-Garcia, Sofía and Pardo-Perez, Eduardo and Thuissard-Vasallo, Israel John and Andreu-Vázquez, Cristina and Molina López, María Yolanda and Pena Huertas, Marina and Guerrero-Gómez, Luis Leonardo and Sanz-Rosa, David and Lorenzo, Felipe Counago},
  title = {Hypofractionated whole breast IMRT with HDR brachytherapy boost in early-stage breast cancer: Long-term results from a single-center},
  journal = {Brachytherapy},
  year = {2024},
  doi = {10.1016/j.brachy.2024.02.009}
}
Kostenlos starten →